There is no known antidote for EPIVIR-HBV. If overdose occurs, the patient should be monitored, and standard supportive treatment utilized, as required.
Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.
EPIVIR-HBV is contraindicated in patients who have experienced a previous hypersensitivity reaction (e.g., anaphylaxis) to lamivudine or to any component of the tablets or oral solution.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/6/2014
Additional Epivir-HBV Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.